TP53 and breast cancer: While there is extensive evidence for the involvement of the well-documented, canonical activated p53 pathway in doxorubicin-induced cell death, recent evidence has suggested that pERK can cause apoptosis in breast cancer cells treated with doxorubicin, regardless of the expression or functioning of p53 (Kumari et al. 2017).